Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bionanomatrix-AB
- Development stage
- Preclinical
- Lead developer
- Endomimetics
- Modality
- Peptides, Small Molecules
- Administration
- Percutaneous
01
Overview
**Bionanomatrix-AB** is a preclinical, drug-eluting angioplasty-balloon coating developed by Endomimetics for peripheral artery disease. The peptide-based, endothelium-mimicking nanomatrix is designed to locally deliver liposome-encapsulated sirolimus together with sustained nitric oxide release to limit neointimal hyperplasia and restenosis while supporting endothelial healing, vasodilation, and reduced platelet-mediated thrombosis after angioplasty. ([endomimetics.com](https://endomimetics.com/pipeline/))
- Other names
- Bionanomatrix AB
02
Targets
FKBP1AsGC (Soluble Guanylyl Cyclase)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on Bionanomatrix-AB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bionanomatrix-AB.